Suppr超能文献

单剂量660毫克缓释萘普生钠治疗术后牙痛的疗效:两项双盲、随机、安慰剂对照试验

Efficacy of single-dose, extended-release naproxen sodium 660 mg in postsurgical dental pain: two double-blind, randomized, placebo-controlled trials.

作者信息

Laurora Irene, An Robert

机构信息

a a Bayer HealthCare Consumer Care , Whippany , NJ , USA.

出版信息

Curr Med Res Opin. 2016;32(2):331-42. doi: 10.1185/03007995.2015.1123680. Epub 2015 Dec 15.

Abstract

OBJECTIVE

To evaluate the efficacy of a novel formulation of extended-release/immediate-release (ER) naproxen sodium over 24 h in a dental pain model.

RESEARCH DESIGN AND METHODS

Two randomized, double-blind, placebo-controlled trials in moderate to severe pain after extraction of one or two impacted third molars (at least one partial mandibular bony impaction). Treatment comprised oral ER naproxen sodium 660 mg (single dose), placebo (both studies) or immediate-release (IR) naproxen sodium 220 mg tid (study 2).

MAIN OUTCOME MEASURES

Primary efficacy endpoint: 24-h summed pain intensity difference (SPID). Secondary variables included total pain relief (TOTPAR), use of rescue medication. All treatment-emergent adverse events were recorded.

CLINICAL TRIAL REGISTRATION

NCT00720057 (study 1), NCT01389284 (study 2).

RESULTS

Primary efficacy analyses: pain intensity was significantly lower over 24 h with ER naproxen sodium vs. placebo (p < 0.001), with significant relief from 15 min (study 2). In study 2, ER naproxen sodium was non-inferior to IR naproxen sodium, reducing pain intensity to a comparable extent over 24 h. TOTPAR was significantly greater with ER and IR naproxen sodium vs. placebo at all time points, with generally comparable differences between active treatments. Significantly more placebo patients required rescue medication vs. ER and IR naproxen sodium from 2-24 h post-dose. Once daily ER naproxen sodium was generally safe and well tolerated, with a similar safety profile to IR naproxen sodium tid.

LIMITATIONS

The studies were single dose, with limited ability to assess efficacy or safety of multiple doses over time. As the imputed pain score meant that estimated treatment differences may have been biased in favor of ER naproxen sodium, a post hoc analysis evaluated the robustness of the results for pain relief.

CONCLUSIONS

A single dose of ER naproxen sodium 660 mg significantly reduced moderate to severe dental pain vs. placebo and was comparable to IR naproxen sodium 220 mg tid. Significant pain relief was experienced from 15 min and sustained over 24 h, resulting in a reduced need for rescue medication. ER naproxen sodium 660 mg once daily is a convenient and effective therapy providing 24 h relief of pain.

摘要

目的

在牙科疼痛模型中评估新型缓释/速释(ER)萘普生钠制剂在24小时内的疗效。

研究设计与方法

两项随机、双盲、安慰剂对照试验,针对拔除一或两颗阻生第三磨牙(至少一颗为部分下颌骨阻生)后的中度至重度疼痛。治疗包括口服660毫克ER萘普生钠(单剂量)、安慰剂(两项研究均使用)或220毫克速释(IR)萘普生钠每日三次(研究2)。

主要观察指标

主要疗效终点:24小时疼痛强度总和差值(SPID)。次要变量包括总疼痛缓解(TOTPAR)、急救药物的使用情况。记录所有治疗中出现的不良事件。

临床试验注册编号

NCT00720057(研究1),NCT01389284(研究2)。

结果

主要疗效分析:与安慰剂相比,ER萘普生钠在24小时内疼痛强度显著更低(p < 0.001),从15分钟起即有显著缓解(研究2)。在研究2中,ER萘普生钠不劣于IR萘普生钠,在24小时内减轻疼痛强度的程度相当。在所有时间点,ER和IR萘普生钠组的TOTPAR均显著高于安慰剂组,活性治疗组之间的差异总体相当。与ER和IR萘普生钠相比,从给药后2至24小时,显著更多的安慰剂组患者需要使用急救药物。每日一次的ER萘普生钠总体安全且耐受性良好,安全性概况与每日三次的IR萘普生钠相似。

局限性

研究为单剂量,评估多剂量随时间变化的疗效或安全性的能力有限。由于推算的疼痛评分意味着估计的治疗差异可能偏向于ER萘普生钠,因此进行了一项事后分析以评估疼痛缓解结果的稳健性。

结论

与安慰剂相比,单剂量660毫克ER萘普生钠能显著减轻中度至重度牙科疼痛,且与每日三次220毫克IR萘普生钠相当。从15分钟起即有显著的疼痛缓解,并持续24小时,从而减少了对急救药物的需求。每日一次660毫克ER萘普生钠是一种方便有效的疗法,可提供24小时疼痛缓解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验